Precisely formulated dual-peptide blend Examined for regenerative pathway modelling Convenient pen delivery system for consistent measurement Manufactured under laboratory-grade standards How to Use (Research Reference Only) Research literature evaluates Synedica BPC 157 & TB 500 40mg Pen using structured protocols in controlled laboratory environments
A decrease in proteasomal activity appears to enhance the underlying condition of Huntingtons disease, Alzheimers disease, Parkinsons disease, and Prion disease
Key takeaway: BPC-157 does not replace mechanical loading, physical therapy, or surgical intervention like natural healing does over time, but in preclinical rodent studies it consistently reproduces or enhances many of the core molecular and cellular signals the body uses during tissue protection and repair
Combining BPC-157 and TB-500 creates what researchers describe as a synergistic healing effect that exceeds what either peptide achieves alone
Thank you for donating, sharing, and advocating.
Consult published literature for dosing parameters